Open AccessA Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients
Author(s) -
Tian Ma,
Alexander D. Fuld,
James R. Rigas,
A. Hagey,
Gary Gordon,
Ethan Dmitrovsky,
Konstantin H. Dragnev
Publication year - 2012
Publication title -
chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.539
H-Index - 54
eISSN - 1421-9794
pISSN - 0009-3157
DOI - 10.1159/000343165
Subject(s) - carboplatin , medicine , lung cancer , neutropenia , cancer , gastroenterology , chemotherapy , pharmacology , cisplatin
ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom